Sources and Guidelines Referenced

Clinical recommendations and physiological frameworks in this guide are drawn from established global endocrine guidelines and peer-reviewed studies: Endocrine Society Clinical Practice Guidelines on Primary Aldosteronism (Funder et al., 2016), Cushing's Syndrome (Nieman et al., 2015; Nieman et al., 2021), Pheochromocytoma and Paraganglioma (Lenders et al., 2014), and Primary Adrenal Insufficiency (Bornstein et al., 2016); European Society of Endocrinology (ESE) and European Network for the Study of Adrenal Tumors (ENSAT) Clinical Practice Guidelines on Adrenal Incidentalomas (Fassnacht et al., 2016; Fassnacht et al., 2023); American Association of Clinical Endocrinology (AACE) Medical Guidelines for the Management of Adrenal Incidentalomas (Zeiger et al., 2009); and World Health Organization (WHO) Endocrine Tumors Classification Standards (2022).

Adrenal Disorders: A Comprehensive Patient Guide

1. Definition and Medical Identity

Adrenal disorders represent a diverse group of clinical conditions characterized by the overproduction, underproduction, or structural neoplasm formation within the paired adrenal glands. Situated superior to the kidneys, these endocrine glands regulate systemic blood pressure, fluid balance, glucose metabolism, immune activity, and acute stress responses through steroid and catecholamine hormones.

The primary medical objective in managing adrenal conditions is restoring endocrine homeostasis. Pathological dysfunction presents either as primary glandular failure, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, autonomous hormone-secreting adenomas, or malignant carcinomas. Treatment paradigms combine precision endocrinological pharmacotherapy, targeted receptor inhibition, physiological hormone replacement, and minimally invasive endocrine surgery known as adrenalectomy.

2. The Underlying Condition or Need

Adrenal disorders develop when structural, autoimmune, genetic, or neoplastic processes disrupt normal hormone biosynthesis and release. Under non-pathological conditions, the adrenal cortex secretes cortisol under the regulation of pituitary adrenocorticotropic hormone (ACTH), secretes aldosterone mediated by the renin-angiotensin-aldosterone system (RAAS), and produces adrenal androgens. The inner adrenal medulla secretes catecholamines—predominantly epinephrine and norepinephrine—in response to sympathetic nervous system activation.

When these regulatory mechanisms fail, profound multi-system pathology occurs. Excess cortisol secretion causes tissue catabolism, central obesity, systemic hypertension, metabolic insulin resistance, and immune suppression. Hypersecretion of aldosterone causes volume expansion, severe low potassium, and resistant hypertension. Excessive catecholamine release triggers dangerous spikes in blood pressure, heart palpitations, and high risks of cardiovascular collapse. Conversely, adrenal hormone deficiency leads to severe fatigue, low blood pressure, vascular collapse, and lethal electrolyte imbalances known as an adrenal crisis. Unchecked neoplastic growth introduces risks of local invasion, vascular compression, and distant metastasis (Fassnacht et al., 2023).

3. How the Treatment Works — Mechanism

Treatment mechanisms operate either by suppressing excessive hormonal pathways, substituting deficient hormonal output, or surgically extirpating pathological gland tissue. Pharmacological management of hypercortisolism utilizes steroidogenesis inhibitors such as metyrapone, ketoconazole, or osilodrostat to block specific enzymatic steps in adrenal steroid biosynthesis. Alternatively, glucocorticoid receptor antagonists, such as mifepristone, block target-tissue receptor activation without lowering circulating cortisol levels (Nieman et al., 2015).

In hyperaldosteronism, competitive mineralocorticoid receptor antagonists like spironolactone or eplerenone prevent aldosterone from binding to distal renal tubular cells, promoting sodium excretion and potassium retention. For catecholamine-secreting pheochromocytomas, competitive alpha-adrenergic receptor blockers (such as phenoxybenzamine or doxazosin) bind irreversibly or reversibly to vascular receptors, preventing life-threatening vasoconstriction during patient handling and surgical removal (Lenders et al., 2014).

When hormone deficiency is present, replacement therapy uses synthetic glucocorticoids (hydrocortisone or prednisone) and mineralocorticoids (fludrocortisone) to replicate physiological diurnal rhythms. Surgical treatment via laparoscopic or retroperitoneoscopic adrenalectomy achieves complete cure in unilateral autonomous tumors by removing the source of hormone hypersecretion while leaving the contralateral normal gland intact (Funder et al., 2016).

4. Types and Variations

Adrenal disorders are categorized by their underlying functional state (hyperfunctioning, hypofunctioning, or non-functioning) and structural anatomy (unilateral lesion, bilateral disease, or diffuse hyperplasia). Clinical strategies vary dramatically according to these classifications.

Clinicians determine the clinical strategy by integrating baseline morning biochemical screening, dynamic suppression or stimulation testing, anatomical CT or MRI imaging, and selective functional testing such as adrenal vein sampling (Funder et al., 2016).

5. Who the Treatment Is For — Indications

Specific indications for medical or surgical management depend on functional, structural, and histological criteria established by international clinical consensus guidelines.

• Unilateral Autonomous Hypersecretion: Confirmed aldosterone-producing adenomas, unilateral cortisol-secreting adenomas, and all functional pheochromocytomas are primary indications for surgical resection (Funder et al., 2016; Lenders et al., 2014).
• Suspicious or Large Adrenal Masses: Non-functioning adrenal masses measuring greater than 4 centimeters, or those demonstrating high non-contrast CT attenuation (greater than 10 Hounsfield Units), rapid growth, or irregular margins require surgical evaluation due to heightened risk of adrenocortical carcinoma (Fassnacht et al., 2023).
• Confirmed Adrenal Insufficiency: Symptomatic low morning serum cortisol combined with elevated plasma ACTH mandates immediate initiation of physiological hormone replacement therapy (Bornstein et al., 2016).
• Bilateral Adrenal Hyperplasia: Idiopathic bilateral hyperaldosteronism or bilateral macronodular adrenal hyperplasia is primarily indicated for targeted long-term pharmacotherapy rather than bilateral surgical removal, preserving baseline adrenal function.

6. Who the Treatment Is NOT For — Contraindications

Applying definitive surgical or aggressive pharmacological interventions requires screening for key clinical contraindications to avoid high complication rates.

• Absolute Contraindications to Surgery: Severe, uncorrected coagulopathy; acute uncompensated heart failure; active systemic sepsis; or inability to tolerate general anesthesia. Uncontrolled catecholamine hypersecretion without prior alpha-adrenergic blockade is an absolute contraindication to surgery due to extreme risk of intraoperative hypertensive crisis or sudden cardiac death (Lenders et al., 2014).
• Relative Contraindications to Surgery: Bilateral adrenal hyperplasia causing primary aldosteronism is generally a contraindication for unilateral surgery, as removal fails to cure hypertension and accelerates postoperative adrenal insufficiency (Funder et al., 2016). Large, locally invasive malignant tumors exceeding 10–12 centimeters are relatively contraindicated for minimally invasive approaches and require open surgical exposure.
• Contraindications to Specific Medical Therapies: Spironolactone is contraindicated in severe chronic kidney disease (stage 4 or 5) or acute hyperkalemia. Ketoconazole therapy is contraindicated in acute or chronic active liver disease due to hepatotoxicity risks (Nieman et al., 2015).

7. Alternatives and Clinical Comparison

Choosing between surgical resection and chronic medical suppression involves balancing procedural risks against lifelong pharmacological compliance, medication side effects, and long-term organ preservation.

Clinicians favor surgical intervention for unilateral hormone-secreting adenomas, confirmed pheochromocytomas, and masses with malignant potential. Conversely, medical therapy is selected for bilateral hyperplastic conditions, poor surgical candidates, or patient preference following balanced risk benefit discussions (Fassnacht et al., 2023).

8. Pre-Treatment Phase

The pre-treatment management phase focuses on exact diagnostic localization, biochemical confirmation, and meticulous physiological optimization to reduce surgical and anesthetic morbidity.

Diagnostic workup requires rigorous protocol testing. Hypercortisolism screening includes 1-milligram overnight dexamethasone suppression testing, 24-hour urinary free cortisol measurements, and late-night salivary cortisol assays (Nieman et al., 2015). Primary aldosteronism screening evaluates the plasma aldosterone-to-renin ratio (ARR), followed by oral or intravenous salt loading confirmation tests. Pheochromocytoma testing relies on measuring plasma free metanephrines or 24-hour urinary fractionated metanephrines (Lenders et al., 2014).

Once biochemical hypersecretion is proven, anatomical localization is performed using high-resolution multidetector CT with thin cuts or MRI. If primary aldosteronism is present and surgery is contemplated in patients over 35 years old, adrenal vein sampling (AVS) is performed to differentiate unilateral adenoma from bilateral hyperplasia, preventing unnecessary adrenalectomy (Funder et al., 2016).

Medical stabilization before surgery is mandatory. Patients with pheochromocytoma undergo 10 to 14 days of progressive alpha-adrenergic blockade (e.g., phenoxybenzamine or doxazosin) to normalize blood pressure and expand intravascular volume, followed by beta-blockers if tachycardia develops. Patients with hypercortisolism receive pre- and perioperative intravenous hydrocortisone to prevent acute postoperative adrenal crisis caused by prolonged suppression of the non-diseased contralateral gland (Bornstein et al., 2016).

9. The Procedure — Step-by-Step Clinical Detail

Adrenal surgery is performed under general endotracheal anesthesia in an inpatient hospital setting. The step-by-step description below details transperitoneal laparoscopic adrenalectomy, the predominant surgical technique for benign or localized adrenal masses.

Step 1: Patient Positioning and Port Placement

The patient is positioned in a lateral decubitus orientation with the side of the lesion elevated at 45 to 60 degrees. Pneumoperitoneum is established using carbon dioxide gas to an intra-abdominal pressure of 12–15 mmHg. Three to four laparoscopic trocars (5mm to 12mm) are inserted beneath the costal margin under direct visualization.

Step 2: Anatomical Exposure and Organ Mobilization

For a right adrenalectomy, the triangular ligament of the liver is divided, and the liver is gently retracted medially to expose the upper renal pole and inferior vena cava. For a left adrenalectomy, the lateral attachments of the colon, spleen, and tail of the pancreas are mobilized medially to open the retroperitoneal space overlying the left kidney and adrenal gland.

Step 3: Vascular Identification and Early Vein Ligation

Direct surgical attention is directed to controlling the primary adrenal vein. On the right side, the short, broad right adrenal vein draining directly into the posterior aspect of the inferior vena cava is double-clipped with surgical clips and divided. On the left side, the left adrenal vein, which drains into the left renal vein, is isolated, clipped, and divided. Early vein ligation prevents intraoperative surging of catecholamines or cortisol during tumor manipulation.

Step 4: Gland Dissection and Hemostasis

Using ultrasonic or bipolar electrocautery devices, the soft tissues, small arterial branches, and perinephric fat surrounding the adrenal gland are systematically divided. Careful dissection preserves the capsule of the adrenal tumor to prevent seeding or tumor rupture.

Step 5: Specimen Retrieval and Closure

The fully dissected adrenal gland is placed inside an impermeable endobag and extracted through the enlarged 12mm trocar site. The operative bed is inspected for absolute hemostasis, irrigation is performed, and trocar fascia and skin sites are closed with absorbable sutures.

10. Immediate Post-Procedure Period

The initial 24 to 48 hours following adrenal intervention require close clinical monitoring in a specialized step-down or intensive care environment, particularly for patients treated for pheochromocytoma or Cushing syndrome.

In patients who underwent resection of a pheochromocytoma, sudden withdrawal of circulating catecholamines can produce sharp hypotension or hypoglycemic episodes. Intravenous fluid expansion and temporary vasopressor support may be required. Serial blood glucose measurements are obtained every two to four hours.

In patients resected for Cushing syndrome, immediate postoperative intravenous hydrocortisone administration (50–100 mg every 8 hours) is initiated and systematically tapered to oral maintenance doses. Serum electrolytes, blood pressure, and urine output are monitored hourly. Criteria for discharge include stable oral fluid intake, transition to oral analgesics, normal electrolyte parameters, and hemodynamic stability on oral medication regimens.

11. Recovery — Short and Long Term

Postoperative recovery after minimally invasive adrenalectomy proceeds rapidly compared to open surgery. Patients generally experience mild incisional pain managed with short courses of oral analgesics and anti-inflammatory medications.

During week 1, patients are encouraged to ambulate frequently to reduce risks of deep vein thrombosis, while avoiding heavy lifting (>10 pounds) or vigorous physical exertion. Most patients return to light desk work within 10 to 14 days. Full physical activity, including strenuous exercise and abdominal training, is restricted for four to six weeks post-procedure.

Long-term recovery and clinical follow-up depend on functional gland status:

• Unilateral Cushing Resection: The contralateral suppressed adrenal gland may require 6 to 18 months to recover normal HPA axis responsiveness. Patients undergo periodic short synacthen (ACTH) stimulation testing to determine when exogenous hydrocortisone can be safely discontinued (Nieman et al., 2015).
• Primary Aldosteronism: Blood pressure improvements unfold over three to six months as vascular remodeling occurs. Plasma aldosterone and renin levels are re-checked at 6 to 12 weeks to confirm endocrine cure (Funder et al., 2016).
• Pheochromocytoma: Plasma or urinary metanephrines are measured 2 to 6 weeks postoperatively to confirm biochemical eradication, followed by annual lifelong surveillance testing to detect rare recurrences (Lenders et al., 2014).

12. Risks, Side Effects, and Complications

Complications following adrenal surgery or medical interventions are stratified by frequency and severity. Overall major complication rates for laparoscopic adrenalectomy performed by high-volume endocrine surgeons remain low (less than 3–5%).

Key warning signs requiring immediate emergency medical evaluation include sudden high fever, progressive abdominal swelling, severe uncontrollable flank or abdominal pain, persistent vomiting, lightheadedness, or acute confusion.

13. Lifestyle and Behavioural Considerations

Patients managing adrenal conditions must incorporate evidence-based lifestyle adaptations alongside their medical or post-surgical care plans.

Patients diagnosed with primary adrenal insufficiency (Addison disease) or undergoing tapering glucocorticoid therapy following Cushing surgery must strictly practice sick-day rules. During periods of minor febrile illness, upper respiratory infections, or severe emotional stress, patients are instructed to double or triple their oral hydrocortisone dose. Every patient must carry a medical alert identification card/bracelet and possess an emergency injectable hydrocortisone kit (100 mg intramuscular act-o-vial) for rapid administration in case of severe trauma, vomiting, or altered consciousness (Bornstein et al., 2016).

Dietary adjustments are customized to the specific underlying hormone profile. Patients with primary aldosteronism or refractory hypertension should adhere to strict dietary sodium restriction (<2,000 mg/day) to reduce fluid retention and arterial stiffness. Conversely, patients with Addison disease require adequate dietary sodium intake, particularly during hot weather or strenuous exercise. Regular cardiovascular exercise is encouraged once surgical sites are fully healed to help normalize body mass index, insulin sensitivity, and vascular tone.

14. How Outcomes Are Measured

Clinical success following adrenal treatment is evaluated using standardized biochemical, radiologic, and clinical endpoints.

For primary aldosteronism, success is defined according to the international Primary Aldosteronism Surgical Outcomes (PASO) criteria, classified as complete, partial, or absent clinical and biochemical success. Complete biochemical success is established by normal suppression of aldosterone-to-renin ratios and restoration of normal serum potassium without supplementation (Funder et al., 2016).

For Cushing syndrome, success is defined by post-operative early morning serum cortisol levels below 1.8 µg/dL (50 nmol/L) within 24 to 48 hours after surgery, indicating complete excision of the autonomous tumor and suppression of remaining normal tissue (Nieman et al., 2015).

In pheochromocytoma, cure is confirmed by persistent normalization of post-operative plasma or 24-hour urinary metanephrines. Cross-sectional imaging (CT or MRI) is performed at 3 to 12 months postoperatively if surgical margins were close, or if malignant features were identified on histopathological examination (Fassnacht et al., 2023).

15. Recent Advances and Current Standard of Care

Over the past decade, management of adrenal disorders has evolved due to improvements in surgical technology, functional nuclear imaging, and molecular genetics.

Standard surgical care for small-to-moderate adrenal masses (<6 cm) has increasingly shifted toward posterior retroperitoneoscopic adrenalectomy (PRA). Performed through three small incisions in the lower back, PRA accesses the adrenal retroperitoneum directly without entering the peritoneal cavity. Clinical trials demonstrate that PRA yields reduced operative time, decreased postoperative pain, and faster recovery compared to traditional transperitoneal laparoscopy.

Functional imaging has advanced through the introduction of highly specific positron emission tomography (PET) radiotracers, such as ⁶⁸Ga-DOTATATE PET/CT for pheochromocytomas and paragangliomas, and ¹¹C-metomidate PET/CT for primary aldosteronism. These techniques improve diagnostic accuracy when anatomical CT or MRI images are equivocal.

Genetic testing is now standard of care for all patients diagnosed with pheochromocytoma or paraganglioma, as up to 30–40% carry germline mutations (e.g., SDHB, VHL, RET, NF1). Identifying these mutations guides lifelong tumor surveillance and cascade screening for family members (Lenders et al., 2014).

16. Common Myths and Misconceptions

Myth: Adrenal fatigue is a recognized medical disorder caused by chronic psychological stress.
Reality: Adrenal fatigue is not an accepted clinical diagnosis recognized by major endocrine societies. While chronic stress impacts the HPA axis, true adrenal insufficiency involves measurable anatomical or autoimmune damage to the adrenal glands confirmed through standardized stimulation tests (Bornstein et al., 2016).

Myth: Surgical removal of one adrenal gland always requires lifelong steroid pills.
Reality: Surgical removal of a single adrenal gland for primary aldosteronism or pheochromocytoma leaves the normal contralateral gland intact, which provides full hormone production without systemic steroids. Lifelong steroid replacement is only required following bilateral adrenalectomy or during temporary recovery of suppressed tissue after Cushing surgery.

Myth: All adrenal nodules discovered on CT scans are cancerous and must be removed.
Reality: Over 80% of unexpectedly discovered adrenal nodules (incidentalomas) are benign, non-functioning cortical adenomas that require neither surgery nor invasive treatment (Fassnacht et al., 2023).

Myth: High blood pressure caused by adrenal disorders cannot be cured.
Reality: Secondary hypertension caused by unilateral aldosterone-producing adenomas or pheochromocytomas can be cured or markedly improved following successful surgical resection (Funder et al., 2016).

Myth: Patients with Addison disease must avoid all exercise and physical activity.
Reality: Patients with stabilized primary adrenal insufficiency can participate in regular physical activity and sports, provided they adjust their glucocorticoid dosing for strenuous endurance events according to clinical guidelines.

Myth: Biopsy of an adrenal mass is routine before deciding on treatment.
Reality: Percutaneous fine-needle biopsy of an adrenal mass is contraindicated in suspected pheochromocytoma due to risks of hypertensive crisis, and is generally avoided in adrenocortical carcinoma due to tumor seeding risks (Fassnacht et al., 2023).

17. Frequently Asked Questions

What are the first warning signs of an adrenal gland disorder?

Early clinical features depend on whether hormone production is elevated or deficient. Symptoms of hormone excess include severe refractory high blood pressure, unexplained rapid weight gain in the chest and abdomen, muscle weakness, and purple skin striae. Symptoms of adrenal deficiency include profound worsening fatigue, unexplained weight loss, low blood pressure, dizziness upon standing, and darkening of the skin folds.

How is an adrenal disorder diagnosed by an endocrinologist?

Diagnosis follows a two-step clinical framework. First, specialized blood, late-night saliva, or 24-hour urine tests measure baseline hormone levels or test response to dynamic stimulation/suppression drugs. Second, if hormonal dysfunction is proven, dedicated high-resolution cross-sectional imaging, such as an adrenal-protocol CT or MRI, is performed to localize structural lesions, adenomas, or hyperplastic glands.

What is the difference between Cushing syndrome and Cushing disease?

Cushing syndrome is the broad clinical umbrella term describing signs and symptoms caused by prolonged excess cortisol from any source, including adrenal tumors or long-term steroid medication. Cushing disease is a specific sub-type of Cushing syndrome caused specifically by an ACTH-secreting pituitary tumor that stimulates non-diseased adrenal glands to produce excessive cortisol.

Is adrenalectomy performed as open or laparoscopic surgery?

Over 80–90% of benign or localized adrenal resections are performed using minimally invasive techniques, such as transperitoneal laparoscopy or posterior retroperitoneoscopic surgery. Open surgical adrenalectomy is reserved for large malignant lesions (typically greater than 6 to 8 cm), tumors demonstrating radiologic invasive features into surrounding organs, or complex adrenocortical carcinomas requiring en bloc lymph node dissection.

What is an adrenal crisis and how is it managed?

An adrenal crisis is a life-threatening medical emergency caused by acute, severe deficiency of circulating cortisol. Symptoms include rapid-onset severe low blood pressure, high fever, intractable vomiting, abdominal pain, high potassium, and confusion. Emergency management requires immediate intravenous injection of 100 mg hydrocortisone followed by rapid intravenous fluid resuscitation with normal saline in a hospital setting.

Why is pre-operative medication required before pheochromocytoma surgery?

Pheochromocytomas store large quantities of catecholamines that can be suddenly released during anesthesia induction or surgical manipulation. Without proper pre-operative preparation using alpha-adrenergic receptor blockers for 10 to 14 days beforehand, intraoperative tumor handling can trigger extreme hypertensive crises, stroke, arrhythmia, or sudden cardiac arrest.

Can a person live normally with only one adrenal gland?

Yes, a single healthy adrenal gland easily produces sufficient amounts of cortisol, aldosterone, and catecholamines to maintain normal bodily function. Following recovery from unilateral adrenalectomy for benign non-cortisol producing tumors, patients generally do not require long-term hormone replacement therapy or permanent activity restrictions.

How long does recovery take after laparoscopic adrenal surgery?

Most patients remain in the hospital for one to two nights following laparoscopic or retroperitoneoscopic adrenalectomy. Walking is started on the day of surgery. Most patients return to light daily routines within 10 to 14 days, with full resumption of unrestricted physical exertion and exercise allowed at four weeks post-procedure.

What is an adrenal incidentaloma?

An adrenal incidentaloma is an unsuspected adrenal mass measuring 1 centimeter or greater discovered during cross-sectional imaging performed for unrelated clinical reasons. Evaluation involves biochemical screening to rule out subtle hormone hypersecretion and radiologic assessment (Hounsfield units on CT) to exclude malignancy.

Will removing an adrenal tumor cure my high blood pressure?

If high blood pressure is caused by a unilateral aldosterone-producing adenoma (Conn syndrome) or pheochromocytoma, surgical removal results in complete cure or substantial improvement of hypertension in 60 to 80% of patients, often allowing reduction or elimination of antihypertensive medications.

What dietary changes are necessary during adrenal treatment?

Patients with primary aldosteronism or hypertension benefit from strict dietary sodium reduction to control blood pressure. Patients with primary adrenal insufficiency must ensure adequate sodium intake and carry supplemental salt during extreme heat. Patients on long-term steroid therapy should consume adequate calcium and vitamin D to protect bone density.

How often is follow-up required after treatment for an adrenal tumor?

Follow-up schedules depend on tumor histology and functional status. Benign non-functioning masses under active surveillance undergo radiologic and biochemical re-evaluation at 12 months. Resected pheochromocytomas or adrenocortical carcinomas require lifetime annual biochemical monitoring and periodic imaging to check for recurrent disease.